Abstract:Cancer immunotherapy has emerged as a transformative approach in oncology, utilizing the body's immune system to specifically target and destroy malignant cells. This review explores the scope and impact of various immunotherapeutic strategies, including monoclonal antibodies, chimeric antigen receptor (CAR)-T cell therapy, checkpoint inhibitors, cytokine therapy, and therapeutic vaccines. Monoclonal antibodies, such as Rituximab and Trastuzumab, have revolutionized treatment paradigms for lymphoma and breast cancer by offering targeted interventions that reduce off-target effects. CAR-T cell therapy presents a potentially curative option for refractory hematologic malignancies, although challenges remain in effectively treating solid tumors. Checkpoint inhibitors have redefined the management of cancers like melanoma and lung cancer; however, managing immune-related adverse events and ensuring durable responses are critical areas of focus. Cytokine therapy continues to play a vital role in modulating the immune response, with advancements in cytokine engineering improving specificity and reducing systemic toxicity. Therapeutic vaccines, particularly mRNA-based vaccines, represent a frontier in personalized cancer treatment, aiming to generate robust, long-lasting immune responses against tumor-specific antigens. Despite these advancements, the field faces significant challenges, including immune resistance, tumor heterogeneity, and the immunosuppressive tumor microenvironment. Future research should address these obstacles through emerging technologies, such as next-generation antibodies, Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-based gene editing, and AI-driven drug discovery. By integrating these novel approaches, cancer immunotherapy holds the promise of offering more durable, less toxic, and highly personalized treatment options, ultimately improving patient outcomes and survival rates.

Single-Chain Fragment Variable: Recent Progress in Cancer Diagnosis and Therapy

Breast cancer immunotherapy using scFv antibody-based approaches, a systematic review

scFv Antibody: Principles and Clinical Application

The Potential of Single-Chain Variable Fragment Antibody: Role in Future Therapeutic and Diagnostic Biologics

The Effect of Anti-Vegf Drugs (bevacizumab and Aflibercept) on the Survival of Patients with Metastatic Colorectal Cancer (Mcrc)

Antibody and antibody fragments for cancer immunotherapy

Personalized Medicine: Recent Progress in Cancer Therapy

Strategies for Bispecific Single Chain Antibody in Cancer Immunotherapy.

Revolutionizing Cancer Treatment: Recent Advances in Immunotherapy

Strategies for Bispecific Single Chain Antibody in Cancer Immunotherapy

Assessment of the Evolution of Cancer Treatment Therapies

Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy

In Vivo Applications of Single Chain Fv (Variable Domain) (scFv) Fragments

The Novel and Promising Weapon to Fight Cancer

Generating improved single-chain Fv molecules for tumor targeting

Advances in immunotherapy in cervical cancer

Promising Diagnostic and Therapeutic Approaches Based on VHHs for Cancer Management

Revolutionizing Cancer Treatment: Unleashing the Power of Viral Vaccines, Monoclonal Antibodies, and Proteolysis-Targeting Chimeras in the New Era of Immunotherapy

Nanobody Engineering: Toward Next Generation Immunotherapies and Immunoimaging of Cancer

Revolutionizing cancer care strategies: immunotherapy, gene therapy, and molecular targeted therapy

Advanced, recurrent, and persistent cervical cancer management: in the era of immunotherapy